LCM
PHAS

Laurion Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Laurion Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-54,072
Closed -$167K – 1410
2018
Q4 		$167K Buy
+54,072
New +$214K ﹤0.01% 979

Other funds holding PHAS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Laurion Capital Management's PHAS Position: Q1 2019 in Review

Laurion Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2019, closing a stake of 54,072 shares — an estimated $167K sold.

Laurion Capital Management first reported a position in PHAS in Q4 2018 and held it in 1 quarter. The position peaked at $167K in Q4 2018. 19 funds tracked by Wall St. Rank hold PHAS as of Q1 2019.

  • Laurion Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Laurion Capital Management sold 54,072 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $167K.
  • Laurion Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Laurion Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $167K in Q4 2018.
  • 19 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on Laurion Capital Management's 13F filing for Q1 2019, filed 8 May 2019.